The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer,
but new platinum agents have been very slow to enter the clinic. Recently, however, there …

The demonstration in the 1960s that cis-diamminedichloroplatinum (II), or cisplatin, inhibits
cellular division of Escherichia coli 1 led to the subsequent discovery that this simple …

Thirty years after the onset of the first clinical studies with cisplatin, the development of
antineoplastic platinum drugs continues to be a productive field of research. This article …

The development of metal-based antitumor drugs has been stimulated by the clinical
success of cis-diamminedichloroplatinum (II)(cisplatin) and its analogs and by the clinical …

Most of the structure/activity rules emerged from the initial studies by Rosenberg and Cleare
and Hoeschele have now been questioned. Specifically:(i) trans compounds are inactive,(ii) …

The research of new platinum drugs active towards cisplatin refractory/resistant tumors has
been mostly focussed on compounds with cis geometry because transplatin, the trans …

The limitations of cisplatin as an anticancer drug have stimulated the search for other
antitumor-active platinum complexes with improved pharmacological properties. The two …

In this paper we summarize the work on the development of trans-platinum complexes as
antitumor agents during the last 15 years. We review the structures and chemical properties …

The discovery in the 1990s of several trans-Pt complexes with in vitro and in vivo activity
against tumor cells sensitive and/or resistant to cisplatin has forced the re-evaluation of the …

The synthesis and chemical characterization of three new transplatinum complexes of
structural formula trans-[PtCl2 (amine)(isopropylamine)](amine= n, n-dimethylamine …